[HTML][HTML] ERK/MAPK signalling pathway and tumorigenesis

YJ Guo, WW Pan, SB Liu… - Experimental and …, 2020 - spandidos-publications.com
Mitogen‑activated protein kinase (MAPK) cascades are key signalling pathways that
regulate a wide variety of cellular processes, including proliferation, differentiation …

The MAPK pathway across different malignancies: a new perspective

M Burotto, VL Chiou, JM Lee, EC Kohn - Cancer, 2014 - Wiley Online Library
The mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathway
is activated by upstream genomic events and/or activation of multiple signaling events in …

The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults

KN Patel, L Yip, CC Lubitz, EG Grubbs, BS Miller… - Annals of …, 2020 - journals.lww.com
Objective: To develop evidence-based recommendations for safe, effective, and appropriate
thyroidectomy. Background: Surgical management of thyroid disease has evolved …

Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study

JD Hainsworth, F Meric-Bernstam… - Journal of Clinical …, 2018 - discovery.ucl.ac.uk
PURPOSE: Detection of specific molecular alterations in tumors guides the selection of
effective targeted treatment of patients with several types of cancer. These molecular …

[PDF][PDF] Integrated genomic characterization of papillary thyroid carcinoma

N Agrawal, R Akbani, BA Aksoy, A Ally, H Arachchi… - Cell, 2014 - cell.com
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …

2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association …

BR Haugen, EK Alexander, KC Bible, GM Doherty… - Thyroid, 2016 - liebertpub.com
Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

[HTML][HTML] BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence

M Xing, R Liu, X Liu, AK Murugan, G Zhu… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive
Papillary Thyroid Cancer With Highest Recurrence - PMC Back to Top Skip to main content NIH …

[HTML][HTML] Association between BRAF V600E mutation and recurrence of papillary thyroid cancer

M Xing, AS Alzahrani, KA Carson… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre …

MS Brose, ME Cabanillas, EEW Cohen, LJ Wirth… - The lancet …, 2016 - thelancet.com
Background About half of patients with papillary thyroid cancer have tumours with activating
BRAF V600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for …

Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next‐generation …

YE Nikiforov, SE Carty, SI Chiosea, C Coyne… - Cancer, 2014 - Wiley Online Library
BACKGROUND Fine‐needle aspiration (FNA) cytology is a common approach to evaluating
thyroid nodules, although 20% to 30% of FNAs have indeterminate cytology, which hampers …